MAXWELLIA’s Post

Check out the interview in Pharmacy Business with the CEO of our portfolio company MAXWELLIA - 'Unlocking the Potential of OTC Medicines: A Q&A with MAXWELLIA CEO'

Check out the interview in Pharmacy Business with the CEO of our portfolio company MAXWELLIA - 'Unlocking the Potential of OTC Medicines: A Q&A with MAXWELLIA CEO'

Pharmacist Alert: FDA Update on Contraceptive Use with Mounjaro (Tirzepatide ) As a pharmacist, staying up-to-date with the latest drug safety information is crucial—especially when new precautions are introduced that can impact patient care. The FDA has recently issued updated guidance regarding the use of oral contraceptives in patients taking Mounjaro (tirzepatide). Although Mounjaro itself does not directly interact with oral contraceptives, the FDA is now recommending that patients consider alternative or dual methods of contraception when using this medication. This precaution is primarily due to the potential gastrointestinal side effects (e.g., nausea, vomiting, diarrhea) associated with Mounjaro, which may interfere with the absorption of oral contraceptives and reduce their effectiveness. Reference: https://lnkd.in/d-DPneRR #FDAUpdate #Mounjaro #Tirzepatide #ContraceptiveUse #PharmacistTips #PatientCare #PharmacyPractice #DrugSafety

I'm excited to share my latest article with Pharmacy Times, "Preparing for PrEP: The Implications of PrEP Medicare Coverage Transition for Pharmacies." This article explores how this significant policy shift impacts pharmacy operations and patient care.

“What CMS’s proposed reimbursement codes could mean for the digital therapeutics industry. The agency proposed three codes clinicians could use to seek reimbursement when prescribing digital therapeutic products” Click on the link below to read the full ariticle. Easy Healthcare Corporation | easy@Home, Premom #digitalinnovation #ttc #drugtests #medicaldevices #healthathome #premom #fertility #empowerment #personalcare

Great recent article about #pharmacists & reducing strain on #emergency This was proven recently in #NovaScotia #communitypharmacies https://lnkd.in/gdMTw28P I appreciate "constructive" comments re: infrastructure/ structural issues and fragmentation. But want to remind my colleagues & friends - these issues aren't specific to #pharmacists providing service but everyone in the system (#physiotherapists #dietitians #walkinclinics). We should all have the information to care best for our patients. And I can practice to my competence in my scope. And I know what the scope is! #pharmacists can do a lot in their communities

SDOH Framework Highlights Role of Health System Specialty Pharmacists: Future potential directions include measuring the impact of clinical pharmacist interventions on referral utility, disease-specific clinical outcomes, patient satisfaction, medication adherence, and absenteeism. #finance #pharmacy #lifesciences

New restrictions on puberty blockers New regulations restrict the prescribing and supply of puberty-suppressing hormones to children and young people under 18. The Government introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland. The emergency ban will last from 3 June to 3 September. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland. During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria/incongruence under the care of these prescribers. The NHS stopped the routine prescription of puberty blocker treatments to under-18s following the Dr Cass Review into gender identity services. In addition, the government has also introduced indefinite restrictions to the prescribing of these medicines within NHS primary care in England, in line with NHS guidelines. The new arrangements apply to gonadotropin-releasing hormone analogues - medicines that consist of, or contain, buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin, or triptorelin. This action has been taken to address risks to patient safety. https://lnkd.in/deQXXfXV

Great news for alopecia sufferers that a new treatment - Ritlecitinib- has been given NICE approval for being prescribed by the NHS. The drug was initially rejected for NICE approval in September last year but this decision revised because the manufacturer offered 'an improved discount' to the NHS. In other words, Ritlecitinib is the same drug now as it was in September 2023. It's just become cheaper and that's why NICE can now approve it for prescribing on the NHS. And this made me reflect on how NICE guidance is perceived by the public. Because until I worked within healthcare myself, I used to see NICE guidance as the absolute gospel of all the treatments that were proven to work. I assumed their judgement was purely on the clinical results. Therefore, if something wasn't being delivered per NICE guidance then it was most likely not reputable and vice versa. However, as I am now learning, NICE aren't just looking at the clinical picture - they are balancing a 'cost to the tax payer/benefit to the whole population' equation. I'm really intrigued to know whether my broader contacts were aware of this? Does this change how you perceive NICE guidance? And with the NHS budget seemingly struggling under its current load, does it motivate you to explore private avenues, or a private funding model that gives the possibility of access to medications that are not NICE approved? N.B. for the avoidance of doubt, I am not saying that NICE guidance is not a really good litmus test or reference point. More pointing out that increasingly we should not assume that NICE guidance is short hand for 'the best that modern medicine can do'. It's the best that the NHS can afford to offer us on a whole population basis. #perception #privategp #costbenefitanalysis #alopecia https://lnkd.in/eY6CAayA

Insightful article that is available free full-text regarding pharmacists' and physicians' perceptions on polypharmacy in older adults. Key Points * All stakeholder groups considered adverse drug reactions and prescribing cascades to be unavoidable. * The complexity of polypharmacy made balancing the medication risk/benefit tipping point very challenging. * Prescribers avoided medication changes unless there was clear evidence of harm. * Medication reconciliation post-hospital discharge compelled prescribing decisions. * Medication reconciliation was viewed as a perilous activity due to communication deficits and a lack of prescribing stewardship. https://lnkd.in/eJiFnU36 #polypharmacy #geriatrics